Logo image of SPRO

SPERO THERAPEUTICS INC (SPRO) Stock News

NASDAQ:SPRO - Nasdaq - US84833T1034 - Common Stock - Currency: USD

0.69  +0.08 (+13.11%)

After market: 0.6999 +0.01 (+1.43%)

SPRO Latest News, Press Relases and Analysis

News Image
16 hours ago - Spero Therapeutics, Inc.

Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update

Pre-specified interim analysis of the ongoing Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI), including...

News Image
5 days ago - Zacks Investment Research

UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates

uniQure (QURE) delivered earnings and revenue surprises of 23.36% and 73.88%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Mentions: QURE

News Image
6 days ago - Zacks Investment Research

Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Misses Revenue Estimates

Avidity Biosciences (RNA) delivered earnings and revenue surprises of -2.27% and 46.68%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Mentions: RNA

News Image
7 days ago - Zacks Investment Research

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates

Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of 23.08% and 13.32%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Mentions: MIRM

News Image
16 days ago - Spero Therapeutics, Inc.

Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer

CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on...

News Image
2 months ago - Zacks Investment Research

Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Tops Revenue Estimates

Spero Therapeutics (SPRO) delivered earnings and revenue surprises of -8.57% and 21.32%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Mentions: NRIX

News Image
2 months ago - Spero Therapeutics, Inc.

Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update

Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to be...

News Image
9 months ago - BusinessInsider

SPRO Stock Earnings: Spero Therapeutics Beats EPS, Beats Revenue for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Spero Therapeutics (NASDAQ:SPRO) just reported results for the second quarter o...

News Image
3 months ago - Spero Therapeutics, Inc.

UPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical...

News Image
4 months ago - Spero Therapeutics, Inc.

Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes

Esther Rajavelu Appointed Interim President and Chief Executive Officer, Frank Thomas Appointed Chairman of the Board Interim Changes to Leadership...

News Image
6 months ago - Spero Therapeutics, Inc.

Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update

Phase 3 PIVOT-PO trial of tebipenem HBr remains on track to complete enrollment in 2H 2025 Reiterate cash runway into mid-2026; Q3 2024 ending...

News Image
10 months ago - InvestorPlace

3 Micro-Cap Moonshots for Fearless Investors

Investors should know the risks of micro-cap stocks before looking into these three high-potential companies with low prices.

Mentions: AMPY ORMP

News Image
a year ago - BusinessInsider

SPRO Stock Earnings: Spero Therapeutics Misses EPS, Misses Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Spero Therapeutics (NASDAQ:SPRO) just reported results for the first quarter of...

News Image
7 months ago - Spero Therapeutics, Inc.

Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024

In vitro data on SPR719 show low propensity for resistance development in NTM-PD MAC strains when administered as a single agent and in combination with...

News Image
7 months ago - Spero Therapeutics, Inc.

Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy

Phase 1 study showed significant lung uptake and enhanced epithelial lining fluid (ELF) and alveolar macrophage (AM) concentrations of SPR719 (active...

News Image
9 months ago - InvestorPlace

SPRO Stock Earnings: Spero Therapeutics Beats EPS, Beats Revenue for Q2 2024

SPRO stock results show that Spero Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

News Image
9 months ago - Spero Therapeutics, Inc.

Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update

Enrollment concluded in the Phase 2a proof-of-concept clinical trial evaluating SPR720 in nontuberculous mycobacterial pulmonary disease (NTM-PD);...

News Image
10 months ago - Spero Therapeutics, Inc.

Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024

CAMBRIDGE, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company,...

News Image
10 months ago - Spero Therapeutics, Inc.

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 03, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company,...

News Image
a year ago - Spero Therapeutics, Inc.

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company,...

News Image
a year ago - Spero Therapeutics, Inc.

Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference

CAMBRIDGE, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company,...

News Image
a year ago - InvestorPlace

SPRO Stock Earnings: Spero Therapeutics Misses EPS, Misses Revenue for Q1 2024

SPRO stock results show that Spero Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

News Image
a year ago - Spero Therapeutics, Inc.

Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update

On track for topline data from SPR720 Phase 2a proof-of-concept trial in treatment-naive and treatment-experienced non-refractory NTM-PD patients, expected...

News Image
a year ago - Spero Therapeutics, Inc.

Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024

CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company,...

News Image
a year ago - Spero Therapeutics, Inc.

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company,...

News Image
a year ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time to start the day with a breakdown of all the biggest pre-market stock movers worth watching on Thursday morning!

Mentions: PRST FWBI HEAR CCTG ...

News Image
a year ago - Spero Therapeutics, Inc.

Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update

On track for topline data from SPR720 Phase 2a proof-of-concept trial in treatment-naive and treatment-experienced non-refractory NTM-PD patients, expected...